GlassScriptPhysician profile
Amanda R Lowe
NPI 1225357619
$3,162.21
in general payments reported to CMS, 2019-2025
29 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $538 · 2021: $728 · 2022: $479 · 2023: $422 · 2024: $421 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $603.55 | 2020-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $487.44 | 2021-2025 | |
| Lilly USA, LLC | $345.65 | 2019-2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $241.16 | 2021-2025 | |
| Amgen INC. | $235.19 | 2020-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $186.85 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $185.66 | 2019-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $115.64 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.28 | 2019-2024 | Xifaxan |
| Daiichi Sankyo INC. | $89.34 | 2020-2022 | |
| Pfizer INC. | $84.77 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.92 | 2023-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $55.38 | 2021 | |
| Dexcom, INC. | $48.59 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $45.69 | 2022-2023 | Gvoke Hypopen |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $35.97 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.42 | 2022 | |
| Sanofi-Aventis U.S. LLC | $27.36 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $23.51 | 2021 | |
| Sobi, INC | $19.62 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.19 | 2025 | Caplyta |
| United Therapeutics Corporation | $18.82 | 2024 | Tyvaso |
| Abbott Laboratories | $17.28 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $16.93 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $15.88 | 2020 | |
| Smith+Nephew, INC. | $14.52 | 2025 | Collagenase Santyl |
| Redhill Biopharma INC. | $14.21 | 2021 | |
| Esperion Therapeutics, INC. | $12.39 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.